multiple signals loaded dendritic cells vaccine

Multiple Signals loaded Dendritic Cells Vaccine is an investigational cell-based immunotherapy designed to enhance antitumor immune responses. This approach involves ex vivo loading of autologous dendritic cells (DCs) with multiple tumor-associated antigens or neoantigens, and often additional immunostimulatory signals, to optimize the activation of both CD4+ and CD8+ T cells upon administration. The "multiple signals" concept refers to the simultaneous presentation of various antigenic peptides or proteins, sometimes combined with adjuvants or co-stimulatory molecules, aiming for a broader and more robust immune response against cancer cells. These vaccines are typically administered via intradermal or intranodal injection in clinical trials for solid tumors such as melanoma, glioblastoma, and other cancers[2][5]. The mechanism relies on DCs' natural ability to process and present antigens via MHC class I and II pathways—thereby priming cytotoxic T lymphocytes (CTLs) as well as helper T cells for targeted tumor cell killing[5].